KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation and Depletion (2018 - 2025)

Historic Depreciation and Depletion for Aquestive Therapeutics (AQST) over the last 8 years, with Q3 2025 value amounting to $139000.0.

  • Aquestive Therapeutics' Depreciation and Depletion fell 1257.86% to $139000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $565000.0, marking a year-over-year decrease of 3615.82%. This contributed to the annual value of $640000.0 for FY2024, which is 4449.26% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Depreciation and Depletion stood at $139000.0, which was down 1257.86% from $140000.0 recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Depreciation and Depletion high stood at $743000.0 for Q1 2021, and its period low was $139000.0 during Q1 2025.
  • For the 5-year period, Aquestive Therapeutics' Depreciation and Depletion averaged around $388736.8, with its median value being $286000.0 (2023).
  • Per our database at Business Quant, Aquestive Therapeutics' Depreciation and Depletion soared by 1424.42% in 2023 and then crashed by 6259.54% in 2024.
  • Aquestive Therapeutics' Depreciation and Depletion (Quarter) stood at $717000.0 in 2021, then tumbled by 52.02% to $344000.0 in 2022, then increased by 14.24% to $393000.0 in 2023, then crashed by 62.6% to $147000.0 in 2024, then decreased by 5.44% to $139000.0 in 2025.
  • Its Depreciation and Depletion stands at $139000.0 for Q3 2025, versus $140000.0 for Q2 2025 and $139000.0 for Q1 2025.